Latest News

SALT LAKE CITY, Utah — Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today reported new data from the 12-month long-term open...
SALT LAKE CITY, Utah — Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in HEALEY...
Cleveland, Ohio – Cleveland Clinic and the University of Western Ontario have been awarded a $4.9 million grant from Helmsley Charitable Trust to build a consortium to develop clinical trial outcome tools for patients with Crohn’s disease and permanent ileostomy. A permanent ileostomy is a surgical procedure to divert stool...
Cleveland, Ohio – Findings from a trial led by Cleveland Clinic show that patients with atrial fibrillation undergoing a transcatheter aortic valve replacement (TAVR) at the same time as a left atrial appendage occlusion (LAAO) procedure using the Watchman™ device had similar outcomes when compared to patients getting TAVR in...
WELLESLEY HILLS, Mass. — Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced results from a completed nonhuman primate (NHP) study comparing CLYM116 to sibeprenlimab, a first-generation anti-APRIL monoclonal antibody. The company is hosting a virtual investor event focused on CLYM116 today, Monday,...